Suzetrigine in TKA

Inclusion Criteria: * Patients undergoing primary TKA with participating surgeons * Age 18 to 80 years old * Planned Discharge to home * Planned use of neuraxial anesthesia * American Society of Anesthesiologist (ASA) Physical Status 1 - 3 * Patients undergoing primary unilateral TKA with participating surgeons Exclusion Criteria: * ASA greater than 3 * Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery) * History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator) * History of QT prolongation * Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device * Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse * Inability to comply with any component of the study protocol * Younger than 18 or greater than 80 years old at the time of enrollment * Patient already on Suzetrigine * Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease/Child Pugh B or C, use of strong CYP3 inhibitors or inducers) * Contraindications to neuraxial anesthesia or any other part of the study protocol * Participation in another investigational drug or device study * Pregnancy * Prior osteotomy of the operative knee * Baseline knee flexion \<60° * History of infection or septic arthritis of the operative knee